NDAORALTABLET
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DAYPRO ALTA (oxaprozin potassium) by Pfizer is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2002.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAYPRO ALTA is an oral nonsteroidal anti-inflammatory drug (NSAID) containing oxaprozin potassium that provides analgesic, anti-inflammatory, and antipyretic effects. It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, thereby decreasing pain and inflammation. The potassium formulation represents a reformulation of the original oxaprozin product.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand is entering a defensive phase likely supporting a smaller, focused team focused on retention and cost management.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of oxaprozin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Oxaprozin is a potent inhibitor of prostaglandin synthesis in vitro. Oxaprozin…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DAYPRO ALTA in a LOE-approaching lifecycle offers limited growth opportunity and smaller team size compared to growth-stage products. Career advancement will depend on cost management, retention strategy, and eventual transition to post-LOE or adjacent portfolio assets.
Brand Manager
Worked on DAYPRO ALTA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.